miR‑4417 targets lncRNA PSMG3‑AS1 to suppress cell invasion and migration in cervical squamous cell carcinoma
- Authors:
- Published online on: April 29, 2021 https://doi.org/10.3892/ol.2021.12763
- Article Number: 502
-
Copyright: © Man et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Although long non‑coding RNA (lncRNA) PSMG3‑AS1 has been reported to participate in cancer biology, its role in cervical squamous cell carcinoma (CSCC) is unknown. The present study aimed to investigate the role of the lncRNA PSMG3‑AS1 in CSCC. The expression levels of PSMG3‑AS1 in both CSCC and non‑tumor tissues from 64 patients with CSCC were measured by reverse transcription‑quantitative PCR. The potential interaction between miR‑4417 and PSMG3‑AS1 was predicted using IntaRNA 2.0. Overexpression of miR‑4417 and PSMG3‑AS1 were achieved in CSCC cells to further explore the potential interaction between them. The effects of overexpression of miR‑4417 and PSMG3‑AS1 on CSCC cell invasion and migration were assessed by Transwell assay. The results revealed that PSMG3‑AS1 expression was upregulated in CSCC tissues, and its high expression levels predicted a poor survival in patients with CSCC. miR‑4417 expression was downregulated in CSCC tissues and was inversely correlated with PSMG3‑AS1 expression. Moreover, miR‑4417 was predicted to interact with PSMG3‑AS1. In CSCC cells, overexpression of miR‑4417 decreased the expression levels of PSMG3‑AS1, while overexpression of PSMG3‑AS1 did not affect miR‑4417 expression. Transwell assay demonstrated that overexpression of PSMG3‑AS1 increased CSCC cell invasion and migration. However, overexpression of miR‑4417 inhibited CSCC cell invasion and migration, and attenuated the effects of PSMG3‑AS1 overexpression in CSCC cells. In conclusion, the present study indicated that miR‑4417 may target PSMG3‑AS1 to suppress cancer cell invasion and migration in CSCC.
